{
  "ticker": "ALA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976442",
  "id": "02976442",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250804",
  "time": "0931",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mhjc297tm8fl.pdf",
  "summary": "**Material Information Summary (ASX: ALA \u2013 Arovella Therapeutics Limited):**  \n\n- **Security Issuance Notice:**  \n  - **Type:** Placement of ordinary shares (ASX: ALA).  \n  - **Shares Issued:** 936,303.  \n  - **Issue Date:** 4 August 2025.  \n  - **Disclosure Exemption:** Issued under Section 708A(5)(e) of Corporations Act (no Part 6D.2 disclosure).  \n  - **Compliance:** Confirms adherence to Chapter 2M (financial reporting) and ASX continuous disclosure rules (sections 674/674A).  \n\nNo other material details (e.g., pricing, use of proceeds, capital structure impact) disclosed.  \n\n**Action:** Monitor for subsequent announcements clarifying capital raised or dilution impact.  \n\n*Note: \"Notes to Editors\" section excluded as non-material for trading decisions.*",
  "usage": {
    "prompt_tokens": 1326,
    "completion_tokens": 194,
    "total_tokens": 1520,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-03T23:48:28.219430"
}